SCHEDULE: Orca Capital AG Reports 4.9% Stake in Phio Pharma

Orca Capital AG has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Phio Pharmaceuticals Corp.

Summary

• Orca Capital AG beneficially owns 280,642 shares of Phio Pharmaceuticals Corp. Common Stock.
• This ownership represents 4.9% of the Issuer's outstanding Common Stock.
• The percentage is calculated based on 5,726,750 shares outstanding, which accounts for the completion of the Issuer's warrant inducement transaction.
• The reported ownership excludes 947,954 shares of Common Stock issuable upon the exercise of warrants, due to a 4.99% beneficial ownership blocker provision.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure and does not contain information that would significantly alter the sentiment towards the company, indicating a neutral impact.

Positives

• The presence of Orca Capital AG as a significant beneficial owner, even if passive, can be viewed as a vote of confidence in Phio Pharmaceuticals Corp.
• The 4.99% blocker provision on warrant exercise limits immediate dilution from this specific holder's warrants, providing some stability regarding the outstanding share count from this source.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Phio Pharmaceuticals Corp. regarding its future operations or financial performance.

Industry Context

This filing is a routine beneficial ownership disclosure and does not provide specific insights into broader industry trends or competitive landscape beyond the fact of an institutional investor's stake in a pharmaceutical company.

Stakeholder Impact

• Shareholders: Orca Capital AG is a significant shareholder, holding a 4.9% stake, which could be viewed as a sign of investor confidence.

Key Dates

Recommendation

This filing is a routine beneficial ownership disclosure by Orca Capital AG, indicating a passive stake of 4.9% in Phio Pharmaceuticals Corp. It does not contain new financial performance data, strategic updates, or other information that would warrant a change in investment thesis. The 4.99% blocker on warrant exercise is a standard provision for passive investors to avoid triggering certain reporting requirements or control implications, and does not suggest any immediate catalyst for a buy or sell decision.

Keywords

Phio Pharmaceuticals, Orca Capital, Schedule 13G, beneficial ownership, common stock, warrants, biotechnology